Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alamab Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and a distinct art unit. The current prosecution activity is focused on an application within the patent office's biotechnology division. This action represents the company's only active matter in the current reporting period. The focus on Biotechnology & Pharmaceuticals reflects the company's primary research and development goals in the medical field.
Marianne Dibrino is the busiest examiner for the portfolio, with 1 pending office action. This action represents the total active prosecution workload for the company, making the review process with Marianne Dibrino the primary focus for their current patent strategy. Practitioners should carefully consider the examiner's previous actions, as Marianne Dibrino is the only individual currently reviewing the company's applications. The outcome of this case will be the sole determinant of the portfolio's immediate progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18757078 | METHOD OF TREATING OSTEOARTHRITIS | DIBRINO, MARIANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18757078 | METHOD OF TREATING OSTEOARTHRITIS | DIBRINO, MARIANNE | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18757078 | METHOD OF TREATING OSTEOARTHRITIS | DIBRINO, MARIANNE | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Jun 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlamab Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marianne Dibrino has the most, with 1 of Alamab Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
